Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.

[1]  S. Hochreiter,et al.  DEXUS: identifying differential expression in RNA-Seq studies with unknown conditions , 2013, Nucleic acids research.

[2]  Katarzyna H. Kaminska,et al.  Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding , 2013, Molecular systems biology.

[3]  A. Kortenkamp,et al.  Seven benzimidazole pesticides combined at sub-threshold levels induce micronuclei in vitro , 2013, Mutagenesis.

[4]  T. Iwawaki,et al.  Microsomal Triglyceride Transfer Protein Inhibition Induces Endoplasmic Reticulum Stress and Increases Gene Transcription via Ire1α/cJun to Enhance Plasma ALT/AST* , 2013, The Journal of Biological Chemistry.

[5]  Janine Ezendam,et al.  Applicability of a keratinocyte gene signature to predict skin sensitizing potential. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  Alexander Levitzki,et al.  Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. , 2013, Annual review of pharmacology and toxicology.

[7]  Julio Saez-Rodriguez,et al.  DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data , 2012, Bioinform..

[8]  A. Statnikov,et al.  Strategic Applications of Gene Expression: From Drug Discovery/Development to Bedside , 2013, The AAPS Journal.

[9]  J. Kleinjans,et al.  A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. , 2012, Carcinogenesis.

[10]  Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing[S] , 2012, Journal of Lipid Research.

[11]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[12]  Magnus Klofsten,et al.  Decision‐Making in the Pharmaceutical Industry: Analysis of Entrepreneurial Risk and Attitude Using Uncertain Information , 2011 .

[13]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[14]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[15]  S. Bartz,et al.  siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids[S] , 2011, Journal of Lipid Research.

[16]  J. Arrowsmith Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[17]  T. Hata,et al.  Pharmacological Characterization of Diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein , 2011, Journal of Pharmacology and Experimental Therapeutics.

[18]  Alexander A. Morgan,et al.  Supplementary Materials for Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011 .

[19]  Roland Eils,et al.  Phenocopy – A Strategy to Qualify Chemical Compounds during Hit-to-Lead and/or Lead Optimization , 2010, PloS one.

[20]  Adetayo Kasim,et al.  Filtering data from high-throughput experiments based on measurement reliability , 2010, Proceedings of the National Academy of Sciences.

[21]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[22]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[23]  Ulrich Bodenhofer,et al.  FABIA: factor analysis for bicluster acquisition , 2010, Bioinform..

[24]  T. Meert,et al.  Effects of phosphodiesterase 10 inhibition on striatal cyclic AMP and peripheral physiology in rats. , 2010, Acta neurobiologiae experimentalis.

[25]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[26]  Hinrich W. H. Göhlmann,et al.  Gene Expression Studies Using Affymetrix Microarrays , 2009, Chapman and Hall / CRC mathematical and computational biology series.

[27]  John A. Tallarico,et al.  Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.

[28]  J. Acquaviva,et al.  The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. , 2009, Biochimica et biophysica acta.

[29]  L. Rudel,et al.  Microsomal Triglyceride Transfer Protein Enhances Cellular Cholesteryl Esterification by Relieving Product Inhibition* , 2008, Journal of Biological Chemistry.

[30]  Shu-Dong Zhang,et al.  A simple and robust method for connecting small-molecule drugs using gene-expression signatures , 2008, BMC Bioinformatics.

[31]  Hinrich W. H. Göhlmann,et al.  I/NI-calls for the exclusion of non-informative genes: a highly effective filtering tool for microarray data , 2007, Bioinform..

[32]  T. Skopek,et al.  Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles , 2007, Journal of Translational Medicine.

[33]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[34]  E. Moler,et al.  Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release , 2006, Journal of biomolecular screening.

[35]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[36]  Véronique Thybaud,et al.  SFTG international collaborative study on in vitro micronucleus test II. Using human lymphocytes. , 2006, Mutation research.

[37]  Daniel Marzin,et al.  SFTG international collaborative study on in vitro micronucleus test I. General conditions and overall conclusions of the study. , 2006, Mutation research.

[38]  Keara M. Lane,et al.  ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. , 2006, Cancer research.

[39]  Klaus Obermayer,et al.  Support Vector Machines for Dyadic Data , 2006, Neural Computation.

[40]  Klaus Obermayer,et al.  A new summarization method for affymetrix probe level data , 2006, Bioinform..

[41]  D. Bol,et al.  Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. , 2006, Pharmacogenomics.

[42]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[43]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[44]  Stephan Heyse,et al.  From targets to leads: the importance of advanced data analysis for decision support in drug discovery. , 2005, Current opinion in drug discovery & development.

[45]  Robert A Jolly,et al.  The role of transcriptome analysis in pre-clinical toxicology. , 2005, Current molecular medicine.

[46]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[47]  Geert Molenberghs,et al.  Graphical Exploration of Gene Expression Data: A Comparative Study of Three Multivariate Methods , 2003, Biometrics.

[48]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[49]  M. Shiomi,et al.  MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. , 2001, European journal of pharmacology.

[50]  S. Garrett,et al.  Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.

[51]  A. Wellstein,et al.  Induction of the Angiogenic Modulator Fibroblast Growth Factor-binding Protein by Epidermal Growth Factor Is Mediated through Both MEK/ERK and p38 Signal Transduction Pathways* , 2000, The Journal of Biological Chemistry.

[52]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[53]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[54]  X. Hua,et al.  SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis , 1994, Cell.

[55]  H. Gylling,et al.  Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. , 1993, Journal of lipid research.

[56]  S. Malawista,et al.  Microtubule Crystals: A New Biophysical Phenomenon induced by Vinca Alkaloids , 1968, Nature.